Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections

Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections

ObjectivesThe identification of the SARS-CoV-2 Omicron variants BA.1 and BA.2 immediately raised concerns about the efficacy of currently used monoclonal antibody therapies. Here, we analyzed the activity of Sotrovimab and Regdanvimab, which are used in clinics for treatment of moderate to severe SA...

Full description

Bibliographic Details
Main Authors: Stefanie Dichtl, Viktoria Zaderer, Viktoria Kozubowski, Hussam Abd El Halim, Eliott Lafon, Lukas Lanser, Günter Weiss, Cornelia Lass-Flörl, Doris Wilflingseder, Wilfried Posch
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
Tixagevimab/Cilgavimab
antibody therapies
COVID-19
3D tissue cell cultures
lung model
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1005589/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1005589/full

Similar Items